Related Experiment Video
Updated: Sep 2, 2025
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Hyperkalemia in Chronic Kidney Disease: Links, Risks and Management
Alexander Sarnowski1, Rouvick M Gama1, Alec Dawson1
1Department of Renal Medicine and Transplantation, St George's NHS University Hospitals NHS Foundation Trust, London, UK.
Insights
Hyperkalemia, a serious condition, is rising due to RAASi medications. Managing potassium in chronic kidney disease (CKD) patients involves various strategies, including new oral binders.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Hyperkalemia presents significant clinical challenges and is increasingly prevalent.
- Medications inhibiting the renin-angiotensin-aldosterone-system (RAASi) are a key driver of rising hyperkalemia rates.
- Chronic kidney disease (CKD) impairs potassium excretion, increasing hyperkalemia risk.
Purpose of the Study:
- To provide a comprehensive overview of hyperkalemia management in CKD patients.
- To explore current guidelines and emerging therapeutic options for hyperkalemia in CKD.
- To highlight the impact of RAASi medications on hyperkalemia prevalence.
Main Methods:
- Review of existing literature and clinical guidelines on hyperkalemia in CKD.
- Analysis of the pathophysiology of potassium dysregulation in CKD.
- Evaluation of current and novel therapeutic strategies for hyperkalemia.
Main Results:
- CKD patients face challenges in maintaining potassium homeostasis due to reduced urinary excretion.
- Management strategies include myocardial protection, potassium shifting, enhanced excretion, dietary control, and treating comorbidities.
- Novel oral potassium binders demonstrate efficacy and are poised for wider clinical adoption.
Conclusions:
- Hyperkalemia is a critical concern in CKD, exacerbated by RAASi use.
- A multifaceted approach is essential for managing hyperkalemia in CKD patients.
- New potassium binders offer a valuable addition to the therapeutic armamentarium for hyperkalemia.
Abstract:
Hyperkalemia is a common clinical problem with potentially fatal consequences. The prevalence of hyperkalemia is increasing, partially due to wide-scale utilization of prognostically beneficial medications that inhibit the renin-angiotensin-aldosterone-system (RAASi). Chronic kidney disease (CKD) is one of the multitude of risk factors for and associations with hyperkalemia. Reductions in urinary potassium excretion that occur in CKD can lead to an inability to maintain potassium homeostasis. In CKD patients, there are a variety of strategies to tackle acute and chronic hyperkalemia, including protecting myocardium from arrhythmias, shifting potassium into cells, increasing potassium excretion from the body, addressing dietary intake and treating associated conditions, which may exacerbate problems such as metabolic acidosis. The evidence base is variable but has recently been supplemented with the discovery of novel oral potassium binders, which have shown promise and efficacy in studies. Their use is likely to become widespread and offers another tool to the clinician treating hyperkalemia. Our review article provides an overview of hyperkalemia in CKD patients, including an exploration of relevant guidelines and nuances around management.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
01:18Chronic Kidney Disease IV: Nursing Management
01:25Chronic Kidney Disease I: Introduction
01:20Acute Kidney Injury V: Interprofessional Care
01:22Acute Kidney Injury VI: Nursing Management
01:24Chronic Kidney Disease II: Clinical Manifestations